Medical laboratory

Sapreme Appoints CEO, BoD Chair and SAB to Advance Development of Next-Generation RNA Therapeutics for Genetically Driven Diseases

Retrieved on: 
tisdag, maj 28, 2024
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, MSD, Medical laboratory, University College Dublin, Self-publishing, Whitehead Institute, Drug development, Molecular medicine, Vaccine, Genetics, RNA, Therapy, Infection, ALS, Free University, Saponin, MIT, MD, MB, Organon, Master of Science, Clinical chemistry, LUMC, Protein, Asos, Duchenne muscular dystrophy, Medicinal chemistry, Psychiatry, Neurology, Complex conjugate, EAN, SAB, Peptide, Damme, Patient, Doctor of Philosophy, Organization, Free University of Berlin, University, Schering-Plough, Leiden University, DMD, Growth, Spacecraft, Cancer, Leiden University Medical Center, Pharmaceutical industry

Sapreme , a biotechnology company focused on developing next-generation RNA therapeutics for patients with genetically driven diseases, today announced the appointment of Marco Timmers, PhD, as Chief Executive Officer and Jeanne Bolger, MD, to Chair of the Sapreme Board of Directors (BoD).

Key Points: 
  • Sapreme , a biotechnology company focused on developing next-generation RNA therapeutics for patients with genetically driven diseases, today announced the appointment of Marco Timmers, PhD, as Chief Executive Officer and Jeanne Bolger, MD, to Chair of the Sapreme Board of Directors (BoD).
  • Before joining Sapreme, he was CEO of Byondis (formerly Synthon Biopharmaceuticals), a clinical-stage biopharmaceutical company developing Antibody-Drug Conjugates (ADCs) targeting intractable cancers and auto-immune diseases.
  • During his time at Byondis, Dr. Timmers also served as Chief Scientific Officer, guiding the company’s clinical strategies and growth.
  • I look forward to working with the team at Sapreme to further advance this innovative platform and accelerate our pipeline of RNA therapeutic candidates addressing a range of genetically driven diseases,” said Marco Timmers, Chief Executive Officer of Sapreme.

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease

Retrieved on: 
torsdag, maj 16, 2024
Medical laboratory, Partnership, Learning, Doctor of Philosophy, Parasitism, Pathology, Patent, Malaria, Apoptosis, Artemisinin, IND, Ocean Biomedical, Vaccine, Plasmodium falciparum, Brown University, MD, Death, Research, Alpert Medical School, Therapy

Kurtis’ novel approach can cause parasite death at a key stage in the malarial cycle, triggering programmed cell death through apoptosis.

Key Points: 
  • Kurtis’ novel approach can cause parasite death at a key stage in the malarial cycle, triggering programmed cell death through apoptosis.
  • This expands patent protection for Dr. Kurtis’ novel discoveries at a time when the most common strains of malaria are showing signs of growing resistance to current Artemisinin-based drugs.
  • Ocean is working to optimize the formulation of its vaccine and therapeutic antibody prior to IND submission and first-in-humans testing.
  • Malaria is the greatest single-agent killer of children on the planet, killing approximately 627,000 individuals in 2022.

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Retrieved on: 
torsdag, maj 16, 2024
Medical laboratory, Patient, Anterior grey column, Pathology, University, MRI, Therapy, Safety, ALS, DSM-IV codes, Biomarker, Division, Stroke, Pharmaceutical industry

“We are very excited to announce the last patient visit in the Phase 1b/2a clinical trial of AJ201 in SBMA, the final milestone before the anticipated topline data are reported in the middle of this year,” said Alexandra MacLean, M.D., Chief Executive Officer of Avenue.

Key Points: 
  • “We are very excited to announce the last patient visit in the Phase 1b/2a clinical trial of AJ201 in SBMA, the final milestone before the anticipated topline data are reported in the middle of this year,” said Alexandra MacLean, M.D., Chief Executive Officer of Avenue.
  • The primary endpoint of the study is to assess safety and tolerability of AJ201 in subjects with clinically and genetically defined SBMA.
  • In April 2024, Avenue hosted a virtual key opinion leader (“KOL”) event highlighting expert perspectives on SBMA.
  • The two featured speakers discussed the characteristics and treatment landscape of SBMA, as well as the trial design and potential of AJ201 in SBMA.

Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Retrieved on: 
onsdag, maj 15, 2024
NRF1, Medical laboratory, GABAA, Partnership, Patient, Pathology, GAERS, Risk, Tramadol, Drug development, Hydromorphone, University, Seizure, FDA, Therapy, Exercise, ALS, DSM-IV codes, Schedule, PO, Epilepsy, CNS, Division, Acquisition, Stroke, Society, Research, Pain, Pharmaceutical industry

MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2024.

Key Points: 
  • MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2024.
  • “The first quarter was incredibly productive for Avenue, as we’ve successfully executed on key milestones across our pipeline of CNS treatments,” said Alexandra MacLean, M.D., Chief Executive Officer of Avenue.
  • In January and May 2024, Avenue raised a total of approximately $9.4 million in gross proceeds from warrant exercise transactions.
  • G&A Expenses: General and administrative expenses for the first quarter of 2024 were $1.3 million, compared to $1.0 million for the first quarter of 2023.

New research confirms that Beethoven had lead poisoning -- but it didn't kill him

Retrieved on: 
måndag, maj 6, 2024
Hearing loss, Death, Medical laboratory, Clinical chemistry, Doctor of Philosophy, AACC, Rifaʽi, Diagnosis, Bermann, Liver, Physician, Harvard Medical School, Genome, Mass spectrometry

WASHINGTON, May 6, 2024 /PRNewswire/ -- To this day, no one knows for certain what caused the liver and kidney disease that led to Ludwig van Beethoven's untimely death. However, a new letter to the editor in the Association for Diagnostics & Laboratory Medicine's (ADLM's, formerly AACC's) journal Clinical Chemistry rules out one popular theory, showing that the composer was exposed to lead levels that were high — but not high enough to kill him.

Key Points: 
  • High lead levels are commonly associated with all of these conditions — and are also associated with other traits of Beethoven's, such as his infamous temper, memory lapses, and chronic clumsiness.
  • However, further studies eventually found that that lock of hair belonged to a woman, not Beethoven.
  • Rifai's group analyzed the locks for lead using two different versions of a highly accurate testing technique known as mass spectrometry.
  • From this, the researchers were able to estimate that Beethoven's blood lead concentration would have been 69 to 71 µg/dL.

ADLM releases guidance to help healthcare professionals navigate respiratory virus testing in a post-COVID world

Retrieved on: 
torsdag, maj 2, 2024
Education, Laboratory, Virology, Medical laboratory, Research, AACC, DRS, Diagnosis, Patient, Pan American Society, Immunodeficiency, Respiratory tract infection, Infection, Lower respiratory tract infection, COVID-19, Vaccine

As respiratory virus testing continues to evolve rapidly in the wake of the COVID-19 pandemic, this guidance aims to ensure that patients benefit fully from emerging technologies in this field.

Key Points: 
  • As respiratory virus testing continues to evolve rapidly in the wake of the COVID-19 pandemic, this guidance aims to ensure that patients benefit fully from emerging technologies in this field.
  • Furthermore, the guidance document discusses the role of diagnostic stewardship in respiratory virus testing, which can help generate accurate and clinically relevant results while conserving laboratory resources.
  • Additionally, the authors of the guidance document propose an algorithm that can help laboratories efficiently decide on the most appropriate tests for a given case of respiratory virus infection.
  • "Laboratorians should remain alert and involved to provide guidance on managing testing and the information obtained from a wider range of testing settings."

The Association for Diagnostics & Laboratory Medicine (formerly AACC) opposes FDA ruling on laboratory developed tests; urges FDA to involve all stakeholders in modernization of laboratory developed test regulation in order to preserve patient access to v

Retrieved on: 
måndag, april 29, 2024
FDA, CMS, Food, Health, Clinical Laboratory, Medical laboratory, AACC, Diagnosis, Patient, Medicare, Communication

Only by having a collaborative discussion can we craft thoughtful and sensible updates to laboratory developed test regulations that advance patient safety while also safeguarding patient access to these essential tests.

Key Points: 
  • Only by having a collaborative discussion can we craft thoughtful and sensible updates to laboratory developed test regulations that advance patient safety while also safeguarding patient access to these essential tests.
  • "As it stands, the FDA's rule would limit patient access to laboratory developed tests.
  • After this phaseout, the FDA will require laboratory developed tests to meet the agency's regulatory standards.
  • As a result, once the phaseout period ends, labs will be faced with significant delays in getting FDA authorization for their laboratory developed tests.

Cannabis Market Flourishes Amid Global Legalization, Driving Concerns About Road Safety

Retrieved on: 
måndag, april 22, 2024
NGC, Financial News, Forensic Medicine Division, Medical laboratory, Workplace, Growth, Medical statistics, Legislation, Public opinion, Cannabinoid, Control, Pharmacokinetics, OTC, ACB, Chocolate, Cannabis, GACP, Edible, Curaleaf, Safety, THC, Certification, Health, Canopy Growth, Collection, Injury, Medical jurisprudence, Offense, IACT, CGC, Lord, Division, USD, University, Vital statistics, OTCQX, Tracking system, International Association, Patient, Principal, College, The College of Medicine, Drug

NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Over the past decade, the cannabis market has undergone significant expansion, driven largely by a wave of legalization efforts across the United States and other parts of the world. As state and national governments reassess their legal stance on cannabis, both for medical and recreational use, the industry has seen a surge in legitimacy and economic interest. In the United States, a majority of states have legalized cannabis in some form, reflecting a shift in public opinion and an acknowledgement of the potential medical benefits and revenue generation opportunities. Globally, countries like Canada, Uruguay, and several European nations have moved towards more liberal cannabis policies, further propelling the market's growth. The financial implications of these legalization efforts are substantial and continue to evolve. According to a report by Grand View Research, the global legal cannabis market size was valued at USD 13.2 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 25.5% from 2022 to 2030. Cannabix Technologies Inc. (OTC: BLOZF) (CSE: BLO), Cronos Group Inc. (NASDAQ: CRON), Canopy Growth Corporation (NASDAQ: CGC), Aurora Cannabis Inc. (NASDAQ: ACB), Curaleaf Holdings, Inc. (OTC: CURLF)

Key Points: 
  • Globally, countries like Canada, Uruguay, and several European nations have moved towards more liberal cannabis policies, further propelling the market's growth.
  • One of the primary concerns is the correlation between cannabis use and impaired driving.
  • Studies have shown that cannabis can significantly impair motor coordination, reaction times, and decision making, which are critical skills for safe driving.
  • NGC also partners with Canadian GACP cultivators to produce and distribute finished cannabis products to both the domestic and global markets.

Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California

Retrieved on: 
måndag, april 22, 2024
University, Vital statistics, Safety, Pharmacokinetics, Tracking system, OTC, Forensic Medicine Division, Collection, Medical laboratory, Injury, Medical jurisprudence, International Association, Medical statistics, Principal, Legislation, College, IACT, Cannabinoid, The College of Medicine, Control, Division

VANCOUVER, British Columbia, April 22, 2024 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana breathalyzer devices for law enforcement and the workplace reports that it will be presenting at the International Association for Chemical Testing (IACT) conference in April.

Key Points: 
  • VANCOUVER, British Columbia, April 22, 2024 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana breathalyzer devices for law enforcement and the workplace reports that it will be presenting at the International Association for Chemical Testing (IACT) conference in April.
  • Cannabix’s Dr. Bruce Goldberger Ph.D., will be presenting on Science & Technology Behind Cannabis Breath Testing and the Company’s marijuana breathalyzer system at the conference workshop session.
  • IACT is composed of governmental agency personnel involved in chemical testing related to traffic safety.
  • IACT has standing committees to address various areas including legislation, training, new equipment and procedures and manufacturers of breath testing equipment.

deepull appoints Kimberle Chapin, MD, as Chief Medical Officer and Wade Stevenson as Chief Marketing and Sales Officer

Retrieved on: 
torsdag, april 18, 2024
Infection, Cepheid variable, University, Molecular genetics, Medical microbiology, Marketing, MD, Brown University, Medical laboratory, Pathology, Patient, Master of Science, Microbiology, UNC Kenan–Flagler Business School, Brigham Young University, MBA, Sepsis, Pharmaceutical industry

Barcelona, Spain – 18 April 2024 – deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification for sepsis and other acute infections, today announces the appointments of Dr Kimberle Chapin as Chief Medical Officer and Wade Stevenson as Chief Marketing and Sales Officer.

Key Points: 
  • Barcelona, Spain – 18 April 2024 – deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification for sepsis and other acute infections, today announces the appointments of Dr Kimberle Chapin as Chief Medical Officer and Wade Stevenson as Chief Marketing and Sales Officer.
  • Jordi Carrera, Chief Executive Officer and Co-Founder of deepull, said: “Kim and Wade are joining at an important time for the business as it progresses its automated sepsis diagnostic test.
  • Previously, Kimberle worked as Chief Medical Officer at Cepheid and for 17 years she was the Director of Clinical Microbiology and Molecular Diagnostics for Infectious Diseases for Lifespan Academic Medical Center.
  • The next few months will be important as we drive forward with the development of this rapid diagnostics solution and build out our commercial strategy,” commented Wade Stevenson, Chief Marketing and Sales Officer at deepull.